Coagulation factor VIIa Recombinant Human

DB00036

biotech approved

Deskripsi

Recombinant human coagulation Factor VIIa (rFVIIa), intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues. Cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi * 121 ± 30 mL/kg [adults] * 153 ± 29 mL/kg [children] * 280 to 290 mL/kg [congenital Factor VII deficiency]
Klirens (Clearance) * 33 - 37 mL/h x kg [healthy] * 1375 +/- 396 mL/hr [severe hemophilia A male children] * 57.3 +/- 9.5 mL/hr/kg [severe hemophilia A male children] * 2767 +/- 385 mL/hr [severe hemophilia A men] * 37.6 +/- 13.1 mL/hr/kg [severe hemophilia A men]

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

93 Data
Catridecacog Catridecacog may increase the thrombogenic activities of Coagulation factor VIIa Recombinant Human.
Aminocaproic acid The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Coagulation factor VIIa Recombinant Human.
Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation factor VIIa Recombinant Human.
Menadione Menadione may increase the thrombogenic activities of Coagulation factor VIIa Recombinant Human.
Tranexamic acid Tranexamic acid may increase the thrombogenic activities of Coagulation factor VIIa Recombinant Human.
Aprotinin Aprotinin may increase the thrombogenic activities of Coagulation factor VIIa Recombinant Human.
Hydrogen peroxide Hydrogen peroxide may increase the thrombogenic activities of Coagulation factor VIIa Recombinant Human.
Aminomethylbenzoic acid Aminomethylbenzoic acid may increase the thrombogenic activities of Coagulation factor VIIa Recombinant Human.
Camostat Camostat may increase the thrombogenic activities of Coagulation factor VIIa Recombinant Human.
Menadione bisulfite Menadione bisulfite may increase the thrombogenic activities of Coagulation factor VIIa Recombinant Human.
Monteplase The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Monteplase.
Lepirudin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Lepirudin.
Bivalirudin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Bivalirudin.
Alteplase The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Alteplase.
Urokinase The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Urokinase.
Reteplase The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Reteplase.
Anistreplase The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Anistreplase.
Tenecteplase The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Tenecteplase.
Abciximab The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Abciximab.
Drotrecogin alfa The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Drotrecogin alfa.
Streptokinase The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Streptokinase.
Dicoumarol The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Dicoumarol.
Argatroban The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Argatroban.
Ardeparin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Ardeparin.
Phenindione The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Phenindione.
Fondaparinux The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Fondaparinux.
Warfarin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Warfarin.
Pentosan polysulfate The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Pentosan polysulfate.
Phenprocoumon The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Phenprocoumon.
Dipyridamole The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Dipyridamole.
Heparin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Heparin.
Enoxaparin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Enoxaparin.
Epoprostenol The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Epoprostenol.
Acenocoumarol The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Acenocoumarol.
4-hydroxycoumarin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with 4-hydroxycoumarin.
Coumarin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Coumarin.
Ximelagatran The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Ximelagatran.
Desmoteplase The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Desmoteplase.
Defibrotide The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Defibrotide.
Ancrod The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Ancrod.
Beraprost The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Beraprost.
Prasugrel The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Prasugrel.
Rivaroxaban The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Rivaroxaban.
Sulodexide The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Sulodexide.
Idraparinux The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Idraparinux.
Cangrelor The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Cangrelor.
Astaxanthin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Astaxanthin.
Apixaban The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Apixaban.
Otamixaban The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Otamixaban.
Amediplase The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Amediplase.
Dabigatran etexilate The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Dabigatran etexilate.
Danaparoid The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Danaparoid.
Dalteparin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Dalteparin.
Tinzaparin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Tinzaparin.
(R)-warfarin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with (R)-warfarin.
Ethyl biscoumacetate The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Ethyl biscoumacetate.
Nadroparin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Nadroparin.
Triflusal The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Triflusal.
Ticagrelor The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Ticagrelor.
Ditazole The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Ditazole.
Vorapaxar The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Vorapaxar.
Edoxaban The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Edoxaban.
Sodium citrate The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Sodium citrate.
Dextran The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Dextran.
Bemiparin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Bemiparin.
Parnaparin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Parnaparin.
Desirudin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Desirudin.
Antithrombin Alfa The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Antithrombin Alfa.
Protein C The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Protein C.
Antithrombin III human The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Antithrombin III human.
Letaxaban The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Letaxaban.
Darexaban The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Darexaban.
Betrixaban The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Betrixaban.
Nafamostat The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Nafamostat.
Gabexate The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Gabexate.
Fluindione The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Fluindione.
Protein S human The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Protein S human.
Brinase The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Brinase.
Clorindione The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Clorindione.
Diphenadione The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Diphenadione.
Tioclomarol The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Tioclomarol.
Melagatran The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Melagatran.
Saruplase The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Saruplase.
(S)-Warfarin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with (S)-Warfarin.
Tocopherylquinone The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Tocopherylquinone.
Dabigatran The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Dabigatran.
Semuloparin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Semuloparin.
Troxerutin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Troxerutin.
Edetic acid The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Edetic acid.
Reviparin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Reviparin.
Dermatan sulfate The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Dermatan sulfate.
SR-123781A The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with SR-123781A.
Limaprost The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Limaprost.

Target Protein

Coagulation factor X F10
Tissue factor F3

Referensi & Sumber

Artikel (PubMed)
  • PMID: 2155
    Blackshear PJ, Holloway PA, Alberti KG: Factors regulating amino acid release from extrasplanchnic tissues in the rat. Interactions of alanine and glutamine. Biochem J. 1975 Sep;150(3):379-87.
  • PMID: 15328151
    Roberts HR, Monroe DM, White GC: The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood. 2004 Dec 15;104(13):3858-64. Epub 2004 Aug 24.
  • PMID: 10584732
    Kenet G, Walden R, Eldad A, Martinowitz U: Treatment of traumatic bleeding with recombinant factor VIIa. Lancet. 1999 Nov 27;354(9193):1879.
  • PMID: 16418464
    O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM: Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006 Jan 18;295(3):293-8.
  • PMID: 15728810
    Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T: Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005 Feb 24;352(8):777-85.

Contoh Produk & Brand

Produk: 33 • International brands: 0
Produk
  • Cevenfacta
    Injection, powder, for solution • 45 KIU • Intravenous • EU • Approved
  • Cevenfacta
    Injection, powder, for solution • 90 KIU • Intravenous • EU • Approved
  • Cevenfacta
    Injection, powder, for solution • 225 KIU • Intravenous • EU • Approved
  • Niastase
    Powder, for solution • 1.2 mg / vial • Intravenous • Canada • Approved
  • Niastase
    Powder, for solution • 2.4 mg / vial • Intravenous • Canada • Approved
  • Niastase
    Powder, for solution • 4.8 mg / vial • Intravenous • Canada • Approved
  • Niastase RT
    Kit; Powder, for solution • 1 mg / vial • Intravenous • Canada • Approved
  • Niastase RT
    Kit; Powder, for solution • 2 mg / vial • Intravenous • Canada • Approved
Menampilkan 8 dari 33 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul